Status:

NOT_YET_RECRUITING

Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current Stimulation Applied Pre-cognitive Behavioral Therapy for Psychosis) Associated to Usual Medication Regimen

Lead Sponsor:

Felicia Iftene

Collaborating Sponsors:

Providence Care Hospital - Providence Care

Queen's University

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The investigators are proposing a new, non-invasive therapeutic model using transcranial alternative current stimulation (tACS), to augment cognitive behavioral therapy for psychosis (CBTp) efficacy i...

Detailed Description

Rationale. 1% Canadians suffer from Schizophrenia (SZ), a neurodegenerative condition with a high rate of relapse, and important personal, familial and social burden, involving a high cost for care. T...

Eligibility Criteria

Inclusion

  • Individuals, with at least 5 years duration of illness, that meet diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual for Mental Disorders-5 and at least one residual positive symptom (as determined by the referring physician);
  • no change in medication regimen for at least 1 months (minor dose adjustments and/or change in medication involving symptoms as sleep, anxiety or medical symptoms such as fever, pain, are permitted);
  • all genders between ages 18-65 (participants 65+ may be eligible depending on performance on cognitive assessment);
  • ability to understand English with reading level at or above grade 6;
  • able to understand and comply with the requirements of the study;
  • provision of written informed consent.

Exclusion

  • current illicit drug substance abuse;
  • current suicidal ideation;
  • current enrollment in CBTp or other formalized psychosocial interventions;
  • undergone vagotomy or surgery upon the vagus nerve;
  • comorbid neurological condition;
  • severe or moderate intellectual disability;
  • currently undergoing hormone therapy;
  • under age 18.
  • NOTE: changes in medication/new hospitalization for worsening symptoms and/or presence of suicidal ideation are no more exclusion criteria for subjects that have passed visit 5 (end of intervention, during follow-ups stage); however the results of the follow-up visits will count at the final results, depending on the severity/imminent danger of symptoms and medication changes, at the best judgment of the principal investigator

Key Trial Info

Start Date :

July 24 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT06889025

Start Date

July 24 2025

End Date

June 1 2027

Last Update

July 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Providence Care Hospital

Kingston, Ontario, Canada, K7L7X3

Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current Stimulation Applied Pre-cognitive Behavioral Therapy for Psychosis) Associated to Usual Medication Regimen | DecenTrialz